HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Dr. Lal PathLabs gets nod to acquire 70% stake in SN Genelab
Sep-25-2026

Dr. Lal PathLabs has received approval for the acquisition of 70% stake in SN Genelab (SN Gene) from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company. The Board of Directors in their meeting held on September 24, 2026, inter-alia considered and approved the same.

The object of acquisition is to strengthen the company’s expertise in genomics and broaden its portfolio of advanced diagnostic services. The transaction will be completed by November 30, 2026. 

Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India. 


  RELATED NEWS >>